KR100606131B1 - 디뉴클레오티드 및 그의 용도 - Google Patents

디뉴클레오티드 및 그의 용도 Download PDF

Info

Publication number
KR100606131B1
KR100606131B1 KR1019997007070A KR19997007070A KR100606131B1 KR 100606131 B1 KR100606131 B1 KR 100606131B1 KR 1019997007070 A KR1019997007070 A KR 1019997007070A KR 19997007070 A KR19997007070 A KR 19997007070A KR 100606131 B1 KR100606131 B1 KR 100606131B1
Authority
KR
South Korea
Prior art keywords
uridine
tetraphosphate
pharmaceutically acceptable
compound
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019997007070A
Other languages
English (en)
Korean (ko)
Other versions
KR20000070807A (ko
Inventor
펜더개스트윌리엄
예륵사벤자민알.
리드아웃쟈넷엘.
싯디퀴수하이브엠.
Original Assignee
인스파이어 파마슈티컬스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/797,472 external-priority patent/US5900407A/en
Priority claimed from US08/798,508 external-priority patent/US5837861A/en
Application filed by 인스파이어 파마슈티컬스 인코퍼레이티드 filed Critical 인스파이어 파마슈티컬스 인코퍼레이티드
Publication of KR20000070807A publication Critical patent/KR20000070807A/ko
Application granted granted Critical
Publication of KR100606131B1 publication Critical patent/KR100606131B1/ko
Assigned to 머크 샤프 앤드 돔 코포레이션 reassignment 머크 샤프 앤드 돔 코포레이션 권리의 전부이전등록 Assignors: 인스파이어 파마슈티컬스 인코퍼레이티드
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
KR1019997007070A 1997-02-06 1998-02-06 디뉴클레오티드 및 그의 용도 Expired - Fee Related KR100606131B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US08/797,472 US5900407A (en) 1997-02-06 1997-02-06 Method of treating dry eye disease with uridine triphosphates and related compounds
US08/797,472 1997-02-06
US8/797,472 1997-02-06
US08/798,508 1997-02-10
US08/798,508 US5837861A (en) 1997-02-10 1997-02-10 Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US8/798,508 1997-02-10
PCT/US1998/002702 WO1998034942A2 (en) 1997-02-06 1998-02-06 Dinucleotides and their use

Publications (2)

Publication Number Publication Date
KR20000070807A KR20000070807A (ko) 2000-11-25
KR100606131B1 true KR100606131B1 (ko) 2006-07-31

Family

ID=27121880

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019997007070A Expired - Fee Related KR100606131B1 (ko) 1997-02-06 1998-02-06 디뉴클레오티드 및 그의 용도

Country Status (16)

Country Link
US (2) US6348589B1 (https=)
EP (1) EP0981534B1 (https=)
JP (1) JP4531867B2 (https=)
KR (1) KR100606131B1 (https=)
CN (1) CN1262556C (https=)
AT (1) ATE325129T1 (https=)
AU (1) AU738907C (https=)
BR (1) BR9807169A (https=)
CA (1) CA2279963C (https=)
DE (1) DE69834392T2 (https=)
DK (1) DK0981534T3 (https=)
ES (1) ES2264197T3 (https=)
NO (1) NO326718B1 (https=)
NZ (1) NZ337225A (https=)
PT (1) PT981534E (https=)
WO (1) WO1998034942A2 (https=)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673779B2 (en) 1996-03-27 2004-01-06 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with dinucleoside polyphosphate compounds or UTP analogues
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
DK0981534T3 (da) 1997-02-06 2006-09-04 Inspire Pharmaceuticals Inc Dinukleotider og deres anvendelser
US7078391B2 (en) * 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
US6596725B2 (en) * 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
US7223744B2 (en) 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US6818629B2 (en) * 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6548658B2 (en) * 1997-07-25 2003-04-15 Inspire Pharmaceuticals, Inc. Di-(uridine 5′)-tetraphosphate and salts thereof
KR20010013797A (ko) 1997-07-25 2001-02-26 인스파이어 파마슈티컬스 인코퍼레이티드 디(우리딘 5'-테트라포스페이트) 염 및 그의 제조방법과용도
US6872710B2 (en) 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
ID29198A (id) * 1997-08-29 2001-08-09 Univ North Carolina Pemakaian uridin 5'-difosfat dan persamaannya untuk mengobati penyakit paru-paru
CA2332540A1 (en) * 1998-05-22 1999-12-02 Benjamin R. Yerxa Therapeutic dinucleotide and derivatives
WO2000039145A1 (en) * 1998-12-23 2000-07-06 The University Of North Carolina At Chapel Hill Targeted gene transfer using g protein coupled receptors
WO2000050024A2 (en) 1999-02-26 2000-08-31 Inspire Pharmaceuticals, Inc. Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof
WO2001002416A1 (en) * 1999-06-30 2001-01-11 Yamasa Corporation Dinucleotide crystals
WO2001012644A1 (en) * 1999-08-17 2001-02-22 Adani, Alexander Dinucleoside 5',5'-tetraphosphates as inhibitors of viral reverse transcriptases and viruses
AU2603101A (en) * 1999-12-22 2001-07-03 Inspire Pharmaceuticals, Inc. Method of treating gastrointestinal tract disease with purinergic receptor agonists
RU2161982C1 (ru) * 2000-01-20 2001-01-20 Общество с ограниченной ответственностью "Клиника Института биорегуляции и геронтологии" Тетрапептид, стимулирующий функцию сетчатой оболочки глаза, фармакологическое средство на его основе и способ его применения
US6864243B1 (en) * 2000-05-12 2005-03-08 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
BR0111297A (pt) * 2000-05-30 2004-01-06 Santen Pharmaceutical Co Ltd Promotor de migração epitelial corneana
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
US7132408B2 (en) * 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7115585B2 (en) * 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US6555675B2 (en) * 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
WO2002048165A2 (en) * 2000-12-15 2002-06-20 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
US20040122223A1 (en) * 2001-02-07 2004-06-24 Davis Jeremy Martin Non-natural nucleotides and dinucleotides
WO2003000056A1 (en) 2001-06-25 2003-01-03 Inspire Pharmaceuticals, Inc. Joint lubrication with p2y purinergic receptor agonists
EP1409503A1 (en) * 2001-07-25 2004-04-21 Celltech R & D Limited Non-natural carbon-linked nucleotides and dinucleotides
WO2003030892A1 (en) * 2001-10-11 2003-04-17 Alcon, Inc. Methods for treating dry eye
KR20050043761A (ko) 2001-11-06 2005-05-11 인스파이어 파마슈티컬스 인코퍼레이티드 염증성 질환의 치료 또는 예방 방법
US7084128B2 (en) 2002-01-18 2006-08-01 Inspire Pharmaceuticals, Inc. Method for reducing intraocular pressure
MXPA05004121A (es) * 2002-10-18 2006-02-17 Molichem Medicines Inc Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
US7326683B2 (en) * 2004-05-06 2008-02-05 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
CA2565545A1 (en) * 2004-05-06 2005-12-08 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
GB0417886D0 (en) * 2004-08-11 2004-09-15 Univ Cardiff Method and means for enhanced pulmonary delivery
GB0502250D0 (en) * 2005-02-03 2005-03-09 Ic Vec Ltd Use
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
US7851456B2 (en) * 2005-06-29 2010-12-14 Inspire Pharmaceuticals, Inc. P2Y6 receptor agonists for treating lung diseases
EP2036567A3 (en) 2005-12-06 2009-12-09 P2-Science APS Modulation of the P2Y2 receptor pathway
US20070249556A1 (en) * 2006-04-21 2007-10-25 Brubaker Kurt E Method of treating inflammation
CN101495497B (zh) * 2006-07-26 2012-03-14 Yamasa酱油株式会社 二(嘧啶核苷5’-)多磷酸的制备方法
EP2049665A2 (en) * 2006-07-28 2009-04-22 Applera Corporation Dinucleotide mrna cap analogs
CA2702094C (en) 2007-10-10 2018-05-01 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
US8168597B2 (en) * 2008-10-22 2012-05-01 Inspire Pharmaceuticals, Inc. Method for treating cystic fibrosis
US9067964B2 (en) 2008-12-18 2015-06-30 Oligomer Sciences Ab Complex and method for enhancing nuclear delivery
WO2012031186A1 (en) 2010-09-03 2012-03-08 Wisconsin Pharmacal Company, Llc. Prebiotic suppositories
PL2614838T3 (pl) * 2010-09-10 2016-10-31 Dikwafozol i kwas hialuronowy lub ich sole do zastosowania w leczeniu zespołu suchego oka
EP2717855A4 (en) 2011-06-07 2014-11-12 Parion Sciences Inc Methods of Treatment
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
EP3431092A1 (en) 2012-03-26 2019-01-23 Santen Pharmaceutical Co., Ltd. Ophthalmic solution comprising diquafosol
HUE039734T2 (hu) 2012-05-29 2019-01-28 Parion Sciences Inc Nátriumcsatorna-blokkoló aktivitású, dendrimerszerû amino-amid-származékok száraz szem és más nyálkahártya-megbetegedések kezelésére
CN108658876A (zh) 2012-12-17 2018-10-16 帕里昂科学公司 3,5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
CA2895512C (en) 2012-12-17 2021-10-19 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
US10323058B2 (en) 2014-07-24 2019-06-18 W. R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
EP3268379B1 (en) 2015-03-09 2023-11-01 W.R. Grace & CO. - CONN. Crystalline form of nicotinamide riboside
US20180125876A1 (en) 2015-05-20 2018-05-10 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and Pharmaceutical Composition for Modulation Polarization and Activation of Macrophages
CN112020363A (zh) 2017-12-22 2020-12-01 益力舒健康公司 烟酰胺核苷氯化物的结晶形式
EP4157288A2 (en) 2020-06-02 2023-04-05 Institut Gustave-Roussy Modulators of purinergic receptors and related immune checkpoint for treating acute respiratory distress syndrom
EP3919062A1 (en) 2020-06-02 2021-12-08 Institut Gustave-Roussy Modulators of purinergic receptors and related immune checkpoint for treating acute respiratory distress syndrom

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002554A1 (en) * 1994-07-15 1996-02-01 Gruppo Lepetit S.P.A. Dinucleoside-5',5'-pyrophosphates
WO1996040059A1 (en) * 1995-06-07 1996-12-19 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of lung disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855304A (en) 1985-01-10 1989-08-08 Repligen Corporation Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals
US5049550A (en) 1987-11-05 1991-09-17 Worcester Foundation For Experimental Biology Diadenosine 5', 5'"-p1, p4,-tetraphosphate analogs as antithrombotic agents
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5837861A (en) * 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US5681823A (en) 1996-05-02 1997-10-28 Prp Inc. P1, P4 -dithio-P2 -P3 -monochloromethylene 5', 5'"-diadenosine P1, P4 -tetraphosphate as antithrombotic agent
US5789391A (en) 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US5763447C1 (en) * 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
JP4118958B2 (ja) 1996-10-09 2008-07-16 ファーマセット，リミティド テトラホスホネート二環式トリス無水物
DK0981534T3 (da) 1997-02-06 2006-09-04 Inspire Pharmaceuticals Inc Dinukleotider og deres anvendelser

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002554A1 (en) * 1994-07-15 1996-02-01 Gruppo Lepetit S.P.A. Dinucleoside-5',5'-pyrophosphates
WO1996040059A1 (en) * 1995-06-07 1996-12-19 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of lung disease

Also Published As

Publication number Publication date
CA2279963C (en) 2008-04-22
ES2264197T3 (es) 2006-12-16
NZ337225A (en) 2002-03-28
EP0981534B1 (en) 2006-05-03
BR9807169A (pt) 2000-06-06
DE69834392D1 (de) 2006-06-08
KR20000070807A (ko) 2000-11-25
JP2001526635A (ja) 2001-12-18
CN1292795A (zh) 2001-04-25
JP4531867B2 (ja) 2010-08-25
US20020082417A1 (en) 2002-06-27
US6977246B2 (en) 2005-12-20
CN1262556C (zh) 2006-07-05
WO1998034942A3 (en) 2000-01-06
EP0981534A2 (en) 2000-03-01
NO993776D0 (no) 1999-08-04
DK0981534T3 (da) 2006-09-04
AU738907B2 (en) 2001-09-27
WO1998034942A2 (en) 1998-08-13
AU738907C (en) 2002-05-16
PT981534E (pt) 2006-09-29
CA2279963A1 (en) 1998-08-13
AU6324298A (en) 1998-08-26
NO993776L (no) 1999-10-06
ATE325129T1 (de) 2006-06-15
US6348589B1 (en) 2002-02-19
NO326718B1 (no) 2009-02-02
DE69834392T2 (de) 2007-02-08

Similar Documents

Publication Publication Date Title
KR100606131B1 (ko) 디뉴클레오티드 및 그의 용도
US5837861A (en) Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
JP3723227B2 (ja) ジ（ウリジン５’）−テトラホスフェート及びその塩の大規模生産のための方法
AU2003217863B2 (en) Nucleotide mimics and their prodrugs
EP0980377B1 (en) Anti-viral pyrimidine nucleoside analogues
EP1280813B1 (en) Anti-viral pyrimidine nucleoside analogues
US7091334B2 (en) Method for large-scale production of di(uridine 5′)-tetraphosphate and salts thereof
US6555675B2 (en) Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US6867199B2 (en) Dinucleoside polyphosphate compositions and their therapeutic use
JP4879398B2 (ja) グリセリルヌクレオチド、それらの製造法および使用
US7939510B2 (en) Di(uridine 5′-)tetraphosphate and salts thereof
MXPA99007236A (en) Certain dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
HK1033464A (en) Certain dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
MXPA99009965A (en) Anti-viral pyrimidine nucleoside analogues
MXPA99011769A (en) Method for large-scale production of di(uridine 5'-tetraphosphate) and salts thereof

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE AMENDMENT REQUESTED 20041014

Effective date: 20051116

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20051116

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline amendment, Appeal Ground Text : 1999 7007070

Appeal request date: 20041014

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2004102000058

PS0901 Examination by remand of revocation

St.27 status event code: A-6-3-E10-E12-rex-PS0901

S901 Examination by remand of revocation
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

St.27 status event code: A-3-4-F10-F13-rex-PS0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20131031

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20140627

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

FPAY Annual fee payment

Payment date: 20160629

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170721

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170721